These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 22040995

  • 1. [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
    Shu LL, Jiang QL, Meng FY, Yang M.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1314-8. PubMed ID: 22040995
    [Abstract] [Full Text] [Related]

  • 2. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
    Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE.
    Cancer; 2004 Jan 01; 100(1):116-21. PubMed ID: 14692031
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
    Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J.
    Leuk Res; 2004 Jun 01; 28(6):613-8. PubMed ID: 15120938
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S, Varadpande L, Paul TR, Digumarti R.
    Leuk Lymphoma; 2007 Nov 01; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract] [Full Text] [Related]

  • 5. Long-term imatinib therapy promotes bone formation in CML patients.
    Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC.
    Blood; 2008 Mar 01; 111(5):2538-47. PubMed ID: 18042796
    [Abstract] [Full Text] [Related]

  • 6. [Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients].
    Jiang Q, Chen S, Jiang B, Jiang H, Lu Y, Huang X, Lu D.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Apr 18; 35(2):136-40. PubMed ID: 12920827
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J.
    Haematologica; 2003 Nov 18; 88(11):1213-20. PubMed ID: 14607749
    [Abstract] [Full Text] [Related]

  • 8. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV, Turkina AG, Kostina IE, Kochkareva IuB.
    Ter Arkh; 2010 Nov 18; 82(2):59-61. PubMed ID: 20387680
    [Abstract] [Full Text] [Related]

  • 9. [Imatinib].
    Urabe A.
    Gan To Kagaku Ryoho; 2003 Aug 18; 30(8):1191-6. PubMed ID: 12938280
    [Abstract] [Full Text] [Related]

  • 10. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
    Medhi K, Raina V, Kumar L, Sharma A, Bakhshi S, Gupta R, Kumar R.
    Leuk Lymphoma; 2010 Oct 18; 51(10):1850-4. PubMed ID: 20849386
    [Abstract] [Full Text] [Related]

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Oct 18; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 12. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V.
    Ann Oncol; 2004 Feb 18; 15(2):358-9. PubMed ID: 14760137
    [No Abstract] [Full Text] [Related]

  • 13. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
    Govind Babu K, Attili VS, Bapsy PP, Anupama G.
    Int Ophthalmol; 2007 Feb 18; 27(1):43-4. PubMed ID: 17410337
    [Abstract] [Full Text] [Related]

  • 14. [Imatinib in treatment of thrombocythemia and other myeloproliferative diseases].
    Shu LL, Yang M.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec 18; 20(6):1507-12. PubMed ID: 23257463
    [Abstract] [Full Text] [Related]

  • 15. Subdural hematomas during CML therapy with imatinib mesylate.
    Song KW, Rifkind J, Al-Beirouti B, Yee K, McCrae J, Messner HA, Keating A, Lipton JH.
    Leuk Lymphoma; 2004 Aug 18; 45(8):1633-6. PubMed ID: 15370217
    [Abstract] [Full Text] [Related]

  • 16. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr 18; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 17. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D, Muir J.
    Lancet; 2001 Dec 01; 358(9296):1903. PubMed ID: 11741656
    [No Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A.
    Ann Hematol; 2004 Dec 01; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract] [Full Text] [Related]

  • 19. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J.
    Blood; 2006 Oct 15; 108(8):2811-3. PubMed ID: 16809614
    [Abstract] [Full Text] [Related]

  • 20. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R.
    Clin Cancer Res; 2002 May 15; 8(5):935-42. PubMed ID: 12006504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.